Market Newsdesk

BREA, Calif., April 18, 2023 (GLOBE NEWSWIRE) — via InvestorWire — Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces today a partnership with Global EV Technology, Inc. and EV Technologies, LLC. (collectively “EVT”), with initial development for improving energy management technology in electric vehicles for greater range and vehicle performance.

Under the newly formed entity, Mullen owns 51% and will consolidate the results of its operations in Mullen Automotive, Inc. Under the agreement between the parties, Global EV Technology will be contributing its technology and existing contracts to MAEO, and Mullen will provide capital, execution and commercialization to grow the business.

Both companies will be contributing and working together on known verified technology for improving existing vehicle performance and extending battery range. As this technology has immediate and key implications for electric vehicles, MAEO’s initial development is focused on improving Mullen’s lineup of commercial and consumer EVs.

The founder of Global EV Technology Inc., and chief scientific officer, Lawrence Hardge, is a successful life-long inventor with a storied career of over 30 yrs. Lawrence’s accomplishments include the following:

• Holds over 120 intellectual prototypes as well as numerous patents and trademarks.
• Inventor of Knock Out 360 Fire Extinguisher. One of the only extinguishers in the U.S. market that is UL approved for use in electric vehicle fires.
• Featured in various magazines, including Barron’s.
• Received Spirit Award from the Detroit City Council for providing Knock Out 360 Extinguishers to local residents.
• Life-long resident of his hometown, Vicksburg, Mississippi, with dedicated focus on helping his community.
• Provided scholarships to high school students who achieved honor roll status, who otherwise could not afford to attend college, as well as provided clothing, computers, housing and utilities.
• Honored by the town of Vicksburg for black history month.

In the late 90s, Lawrence was convicted of a state crime, which was ultimately expunged. Despite these challenges, Lawrence focused his energy and attention on his natural gift for inventions related to electrical equipment and batteries and has dedicated his career on bringing them to market.

“My partnership with Mullen is very important to help scale this energy technology and bring it to our existing and future customers,” said Hardge.

“Lawrence is a talented inventor, and we are excited to begin working with him on improving electric vehicle performance,” said David Michery, CEO and chairman of Mullen Automotive. “We are always looking for forward-thinking and ground-breaking technology opportunities and are pleased to partner with Global and EV Technologies.”

About Mullen

Mullen Automotive (NASDAQ: MULN) is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in two Company owned United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. The Mullen FIVE, the Company’s first electric crossover, is slated for delivery in 2024 and features an award-winning design and its patented PERSONA technology that utilizes facial recognition to personalize the driving experience for every individual. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana.

To learn more about the Company, visit www.MullenUSA.com.

Forward-Looking Statements

Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Mullen and are difficult to predict. Examples of such risks and uncertainties include but are not limited to: (i) whether Global EV Technology, Inc., along with EV Technologies, LLC will perform the obligations under the agreement with the Company; whether the joint venture between Mullen and Global EV Technology, Inc., along with EV Technologies, LLC will be a success; whether MAEO will be successful in its objectives of advancing energy management systems in motor vehicles or otherwise; whether the technology contributed to MAEO by Global EV Technologies will be considered “groundbreaking” or prove effective, reliable or improve electric vehicle range and vehicle performance; whether MAEO will be successful in implementing or scaling the technology or bringing it to market and, if so, when that may be; and whether MAEO will successfully fulfill purchase orders or contracts relating thereto; (ii) whether the commercial product launches contemplated for 2023 will materialize within the slated timelines; (iii) Mullen’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (iv) Mullen’s ability to maintain existing, and secure additional, contracts with manufacturers, parts and other service providers relating to its business; (v) Mullen’s ability to successfully expand in existing markets and enter new markets; (vi) Mullen’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (vii) unanticipated operating costs, transaction costs and actual or contingent liabilities; (viii) the ability to attract and retain qualified employees and key personnel; (ix) adverse effects of increased competition on Mullen’s business; (x) changes in government licensing and regulation that may adversely affect Mullen’s business; (xi) the risk that changes in consumer behavior could adversely affect Mullen’s business; (xii) Mullen’s ability to protect its intellectual property; and (xiii) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Mullen with the Securities and Exchange Commission. Mullen anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Mullen assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Mullen’s plans and expectations as of any subsequent date.

Contact:
Mullen Automotive, Inc.
+1 (714) 613-1900
www.MullenUSA.com

Corporate Communications:

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

YARDLEY, Pa., April 18, 2023 (GLOBE NEWSWIRE) — OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of 54,000 shares of its common stock to three new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4)

The stock options were granted to the new employees on their hire date April 17, 2023 with an exercise price of $2.05 which is equal to the closing price of the company’s common stock as reported by Nasdaq on the grant date.

The stock options have a 10-year term and vest over four years, with one-fourth of the shares underlying the stock option vesting on the first anniversary of the grant date and the remainder vesting in thirty-six equal monthly installments thereafter. Vesting of the stock options is subject to continued service with the company through the applicable vesting date.

About Optinose

Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

Optinose Investor Contact

Jonathan Neely
[email protected]
267.521.0531

SHANGHAI, China, April 18, 2023 (GLOBE NEWSWIRE) — Xiao-I Corporation (Nasdaq: AIXI) (“Xiao-I” or “the Company”), a leading cognitive artificial intelligence enterprise in China, today announced that it will release its unaudited financial results for the full year 2022 before the U.S. market opens on Wednesday, April 26, 2023. The Company will conduct a corresponding conference call at 8:00 a.m. U.S. Eastern Time (8:00 p.m. China Time) to discuss the results.

	What:	Xiao-I Full Year (ended December 31, 2022) Earnings Call
	When:	8:00 a.m. U.S. Eastern Time on Wednesday, April 26, 2023
	Webcast:	ir.xiaoi.com/events

To join the conference call via telephone, participants must use the following link to complete an online registration process. Upon registering, each participant will receive email instructions to access the conference call, including dial-in information and a PIN number allowing access to the conference call. This pre-registration process is designed by the operator to reduce delays due to operator congestion when accessing the live call.

Online Registration:
https://register.vevent.com/register/BIa6261524526c403d9c15cac8e9e5361d

Participants who have not pre-registered may join the webcast by accessing the link at ir.xiaoi.com/events.

A live and archived webcast of the conference call will be available on the Investors section of Xiao-I’s website at www.xiaoi.com.

About Xiao-I Corporation

Xiao-I Corporation is a leading cognitive intelligence enterprise in China that offers a diverse range of business solutions and services in artificial intelligence, covering natural language processing, voice and image recognition, machine learning and affective computing. Since its inception in 2001, the Company has developed an extensive portfolio of cognitive intelligence technologies that are highly suitable and have been applied to a wide variety of business cases. Xiao-I powers its cognitive intelligence products and services with its cutting-edge, proprietary AI technologies to enable and promote industrial digitization, intelligent upgrading, and transformation.

For investor and media inquiries, please contact:

Ms. Sarah Gu
Phone: +1 5713269722
Email: [email protected]

BOTHELL, Wash., April 18, 2023 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the acceptance of an oral presentation containing new data from the Company’s CC-42344 Phase 1 influenza A study at the 7^th Annual International Society for Influenza and Other Respiratory Virus Diseases’ (ISIRV) Antiviral Group Conference. Sam Lee, Ph.D., President and co-CEO, will present “First-in-Human Study of CC-42344, a Novel Broad-Spectrum Influenza A Polymerase PB2 Inhibitor” on May 4, 2023 at 11:05 a.m. Pacific time. The conference theme is “Advancing Respiratory Virus Therapeutics: Lessons Learned from COVID-19” and the event is being held May 3-5 in Seattle.

“We are excited to share additional data from our Phase 1 study with CC-42344 in influenza A and to outline next steps for our compound at this well-respected conference,” said Dr. Lee. “We plan to file a regulatory submission for a Phase 2a influenza A human challenge study that we expect to initiate in the second half of 2023.”

Cocrystal intends to issue a press release summarizing the new data presented at the conference and to post the conference slides to the Company’s website following Dr. Lee’s presentation.

About CC-42344

CC-42344 is a novel PB2 inhibitor discovered using Cocrystal’s proprietary structure-based drug discovery platform technology. CC-42344 targets the influenza polymerase complex, an essential enzyme required for the viral replication. In vitro testing showed CC-42344’s potent antiviral activity against influenza A strains, including pandemic and seasonal strains, as well as against strains resistant to Tamiflu^® and Xofluza^®.

About ISIRV

The International Society for Influenza and other Respiratory Virus Diseases (ISIRV) is an independent and international scientific professional society promoting the prevention, detection, treatment and control of influenza and other respiratory virus diseases. ISIRV was founded in 2005 as the first scientific society with a fully worldwide remit focused on influenza and respiratory virus disease. As a global scientific society, ISIRV fulfils this mission through promoting the exchange and dissemination of information, facilitating the interaction of scientists and of public health specialists and the promotion of international collaborative efforts against these diseases. More information is available here.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s plans and anticipated timelines to begin its Phase 2a human challenge study with its oral PB2 inhibitor CC-42344 in the second half of 2023. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from inflation, interest rate increases, the current banking crisis and the Ukraine war on our Company, our collaboration partners, and on the U.S. and U.K. and global economies, including manufacturing and research delays arising from raw materials and labor shortages, supply chain disruptions and other business interruptions including any adverse impacts on our ability to obtain raw materials and other supplies as well as similar problems with our vendors and our current Contract Research Organization (CRO) and any future CROs and Contract Manufacturing Organizations, the results of the studies for CC-42344 , the ability of our CROs to recruit volunteers for, and to proceed with, clinical studies, our and our collaboration partners’ technology and software performing as expected, financial difficulties experienced by certain partners, the results of future preclinical and clinical trials, the impact of COVID-19 (including long-term and pervasive effects of the virus), general risks arising from clinical trials, receipt of regulatory approvals, regulatory changes, and the potential development of effective treatments by competitors. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2022. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:

LHA Investor Relations
Jody Cain
310-691-7100
[email protected]

Media Contact:

JQA Partners
Jules Abraham
917-885-7378
[email protected]

# # #

– Innovative Licensing and Access Pathway designation is intended to accelerate the regulatory review process in the United Kingdom –

– Ixo-vec has also been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) –

REDWOOD CITY, Calif., April 18, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Ixo-vec (ixoberogene soroparvovec), an investigational gene therapy for the treatment of wet AMD, an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP). The Innovation Passport is the first step in the ILAP process, triggering the MHRA and its partner agencies, including the National Institute for Health and Care Excellence (NICE) and the National Health Service (NHS) England, to partner with Adverum to charter a roadmap for regulatory and development milestones with the goal of early patient access in the United Kingdom (U.K.)

“Our ILAP designation recognizes the innovative potential of Ixo-vec to deliver long-term, therapeutic levels of aflibercept after a single intravitreal injection based on the two-year data from our OPTIC trial. The OPTIC data indicates a greater than 80% reduction in annualized anti-VEGF injections with more than 50% of the trial subjects being supplemental injection-free at two years post-treatment with Ixo-vec, which data is suggestive of a functional cure,” commented Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. “The current standard of care in wet AMD, requires frequent anti-VEGF injections in the eye that can be a lifelong burden for many patients and their caregivers. We believe Ixo-vec has the potential to provide an in-office treatment option that is durable and safe, provides cost-savings, and addresses the needs of wet AMD patients and their families, retina specialists and health systems worldwide. We look forward to leveraging the benefits of ILAP designation, as we continue our development of Ixo-vec.”

“The ILAP designation grants us enhanced regulatory and market access interactions and a potentially faster path towards approval in the U.K. Ixo-vec has already received Fast Track Designation by the FDA and PRIME designation by the EMA,” said Star Seyedkazemi, PharmD, chief development officer of Adverum Biotechnologies. “Our LUNA trial is ongoing, and we plan to provide interim datasets for a percentage of participants at 14 weeks, including aflibercept protein levels, in the third quarter of 2023, as well as preliminary efficacy and safety data in the fourth quarter.”

About Wet Age-Related Macular Degeneration

Wet AMD, also known as neovascular AMD or nAMD, is an advanced form of AMD affecting approximately 10% of patients living with AMD. Wet AMD is a leading cause of blindness in people over 65 years of age, with approximately 20 million individuals worldwide living with this condition. New cases of wet AMD are expected to grow significantly worldwide as populations age. AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately 10% of those cases.

About Ixo-Vec in Wet AMD

Adverum is developing ixoberogene soroparvovec (Ixo-vec), its clinical-stage gene therapy product candidate, for the treatment of wet AMD. Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require surgery to administer the gene therapy under the retina (sub-retinal approach), Ixo-vec is designed to be administered as a one-time IVT injection in the physician’s office, deliver long-term efficacy, reduce the burden of frequent anti-vascular endothelial growth factor (VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD. In recognition of the need for new treatment options for wet AMD, the U.S. Food and Drug Administration granted Fast Track designation for Ixo-vec for the treatment of wet AMD. Ixo-vec also received PRIME designation from the European Medicines Agency and the Innovation Passport from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency for the treatment of wet AMD.

About LUNA Trial of Ixo-vec in Wet AMD

The LUNA trial is a double-masked, randomized, Phase 2 trial being conducted at approximately 40 sites in the U.S. and Europe. LUNA will evaluate Ixo-vec in subjects with wet AMD who are 50 years or older and have demonstrated a response to anti-VEGF treatment. Up to 72 subjects will be randomized equally between the previously evaluated 2E11 vg/eye dose and a new, lower 6E10 vg/eye dose. Four prophylactic steroid regimens will be studied with the aim of establishing a prophylactic corticosteroid regimen with minimal need for inflammation management post prophylaxis. Prophylactic regimens being evaluated include 22 weeks of a tapered regimen of topical difluprednate (Durezol^®), a single administration of IVT dexamethasone (Ozurdex^®), and a combination of either topical Durezol^® or IVT Ozurdex^® with up to 10 weeks of a tapered regimen of oral prednisone. All four prophylactic corticosteroid regimens in LUNA cover the period of peak immunogenicity observed in non-clinical studies and in the Phase 1 OPTIC study.

The LUNA trial primary endpoints are mean change in best corrected visual acuity (BCVA) from baseline to one year as well as the incidence and severity of adverse events. Important secondary endpoints in LUNA include the mean change in central subfield thickness (CST) from baseline to one year and assessing the effectiveness of prophylactic corticosteroid regimens on minimizing inflammation. Additionally, LUNA will assess aflibercept protein levels starting at Week 14 and include an interim analysis at Week 26. Study participants will have the option to enroll in a long-term extension study.

About Adverum Biotechnologies

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.

Forward-looking Statements

Statements contained in this press release regarding events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements regarding the potential benefits of Ixo-vec, the effectiveness of the prophylactic corticosteroid regimens, the LUNA study design, the timing of LUNA enrollment, the approval path in the United Kingdom, and the timing of preliminary data from the LUNA trial. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including risks inherent to, without limitation: Adverum’s novel technology, which makes it difficult to predict the timing of commencement and completion of clinical trials; regulatory uncertainties; enrollment uncertainties; the results of early clinical trials not always being predictive of future clinical trials and results; and the potential for future complications or side effects in connection with use of Ixo-vec. Additional risks and uncertainties facing Adverum are set forth under the caption “Risk Factors” and elsewhere in Adverum’s Securities and Exchange Commission (SEC) filings and reports, including Adverum’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 30, 2023. All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Corporate, Investor and Media Inquiries

Anand Reddi
Vice President, Head of Corporate Strategy, External Affairs and Engagement
Adverum Biotechnologies, Inc.
T: 650-649-1358
E: [email protected]

TORONTO and NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) — AcuityAds Holdings Inc. (TSX: ILLM, Nasdaq: ILLM), a leading digital advertising software company focusing on journey advertising, (the “Company” or “illumin”) announced today that it has rebranded to illumin, the namesake of its revolutionary platform. As part of this rebranding, while the Company retains its legal name “AcuityAds Holdings Inc.”, it will now be doing business as “illumin”. The Company’s new brand name reflects the platform’s success and adoption in the market, and the company’s mission to illuminate the path for brands to connect with their customers through the power of data-driven advertising.

illumin’s journey advertising platform enables brands and agencies to reach consumers at every stage of the marketing journey from awareness to conversion. Using an intuitive drag-and-drop interface, marketers can leverage advanced machine learning algorithms that let them deliver the right message at the right time on the right channels. The platform also provides full-funnel real-time data analytics and insights that help brands optimize their campaigns and drive measurable results.

“We are thrilled to complete our transition to illumin and introduce even more marketers to our journey advertising platform,” said Tal Hayek, CEO of illumin. “As consumer needs evolve it’s essential for brands to have a holistic view of their customers’ journeys and the ability to evolve and pivot their campaigns alongside changing consumer behavior. illumin lets marketers engage with their customers in a meaningful way at every touchpoint, whether that be through display advertising, native ads, digital-out-of-home, or many other digital formats in between. Our platform empowers brands and agencies, letting marketers think outside of traditional line items and execute their campaigns the way they originally envisioned them.”

Much like the consumer journey, illumin’s brand journey has evolved, going beyond simply changing a logo or name, and rethinking the way marketers create their media campaigns. The rebranding and introduction of the journey advertising platform are a culmination of a strategic effort by illumin to position itself for future growth and innovation.

“The evolution of our brand reflects the growth of illumin’s platform alongside an evolving media landscape,” said Tony Vlismas, Vice President of Marketing at illumin. “Today we complete that evolution and start defining exactly what journey advertising means to marketers and the brands they service.”

illumin’s journey advertising platform has already received significant interest from brands and agencies across multiple industries, including CPG, retail, health, travel, politics, and finance. The company plans to continue to invest in innovation, expand its capabilities, and provide exceptional service to its clients.

About illumin:

illumin is a journey advertising platform that enables marketers to reach consumers at every stage of their journey by leveraging advanced machine learning algorithms and real-time data analytics. The company’s mission is to illuminate the path for brands to connect with their customers through the power of data-driven advertising. Headquartered in Toronto, Canada, illumin serves clients across North America, Latin America, and Europe. illumin is a business name of AcuityAds Holdings Inc. which the Company uses as an operating name for its business.

For more information, visit illumin.com

Media contacts:

Tony Vlismas, VP Marketing
illumin | [email protected]

Daniel Gordon, Investor Relations Manager
illumin | [email protected]

Babak Pedram Investor Relations – Canada
Virtus Advisory Group Inc. | [email protected]

David Hanover Investor Relations – U.S.
KCSA Strategic Communications | [email protected]

Disclaimer in regard to forward-looking statements:

Certain statements included herein constitute “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Investors are cautioned not to put undue reliance on forward-looking statements. Except as required by law, the Company does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.

CHICAGO, April 18, 2023 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) announced today it is leveraging its acquisition of Neustar to expand its partnership with Datavant, the leader in helping organizations securely connect health data, to offer de-identified patient insights and measurement solutions for HIPAA-focused healthcare brands.

The partnership will enable Datavant’s ecosystem of partners to connect to demographic data available in TruAudience®, TransUnion’s comprehensive suite of solutions. The integration will enable healthcare and pharmaceutical companies to improve customer outcomes across the full lifecycle of patient engagement, especially measurement of outreach effectiveness.

“We are thrilled to enable TransUnion to connect their demographic and lifestyle data to healthcare data while Datavant software enables de-identification tools to help customers protect patient privacy,” said Dan Scudder, Head of Ecosystem at Datavant. “Patient outcomes are highly impacted by their environment so this data is important for contextualizing the patient journey and enabling more effective efforts to reach patients in need.”

Datavant’s industry-leading software generates irreversible, encrypted tokens to enable TransUnion to match de-identified patient demographic data with healthcare clients’ first-party and licensed third-party data. This enables organizations to better understand, reach, and measure the effectiveness of campaigns to specific audiences.

Datavant’s privacy-first data connectivity solutions are used by the top 30 pharma brands and more than 2,000 hospitals and 15,000 clinics.

TruAudience solutions marry the expansive consumer data, audience building, and targeting capabilities of TransUnion and Neustar into a comprehensive and interoperable suite of privacy-first solutions. Additionally, the product suite offers closed-loop marketing measurement. TruAudience solutions power these capabilities for the leading brands, agencies, publishers, data owners, and technology providers.

“Datavant enables us to provide the advanced de-identification capabilities needed for patient health information, and bring the data-driven marketing and measurement capabilities of TruAudience solutions to the healthcare and pharmaceutical industries,” said Michael Schoen, EVP of Marketing Solutions at TransUnion. “The U.S. healthcare and pharma industries are expected to spend nearly $18 billion dollars on digital advertising in 2023 alone, and we’re enabling them to spend these dollars in the most effective way possible.”

For more information about TruAudience solutions, please visit https://www.transunion.com/truaudience.

About Datavant

Datavant’s mission is to connect the world’s health data to improve patient outcomes. Datavant works to reduce the friction of data sharing across the healthcare industry by building technology that protects the privacy of patients while supporting the linkage of patient health records across datasets. Learn more about Datavant at www.datavant.com.

About TransUnion (NYSE:TRU)

TransUnion is a global information and insights company with over 12,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. Through our acquisitions and technology investments we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with more confidence and achieve great things. We call this Information for Good® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world. http://www.transunion.com/business

Contact	David Blumberg
	TransUnion
E-mail	[email protected]
Telephone	312-972-6646

WATERTOWN, Mass., April 18, 2023 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company’s chief executive officer and president, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, April 25, 2023 at 3:00 p.m. ET at the Stifel 2023 Targeted Oncology Days Conference taking place virtually.

To access the live webcast of this fireside chat, visit the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations. A replay of the webcast will be available via the same link for 90 days following the event.

About Acrivon Therapeutics

Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform enables the creation of drug-specific proprietary OncoSignature^® companion diagnostics that are used to identify the patients most likely to benefit from Acrivon’s drug candidates. Acrivon is currently advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types. Acrivon’s ACR-368 OncoSignature^® test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from past third party Phase 2 trials in patients with ovarian cancer treated with ACR-368. In addition to ACR-368, Acrivon is also leveraging its proprietary AP3 precision medicine platform for developing its internally-discovered preclinical stage pipeline programs targeting two critical nodes in the DNA Damage Response, or DDR, including WEE1, a protein serine/threonine kinase, and the closely related PKMYT1.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.

Investor and Media Contacts:

Alexandra Santos
[email protected]

Aljanae Reynolds
[email protected]

• NXP800 demonstrated robust antitumor activity in two patient-derived xenograft (“PDX”) models of cholangiocarcinoma
• Research conducted by investigators from the Mayo Clinic in Rochester, MN

Fort Lee, NJ, April 18, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today provided highlights from the poster presentation of NXP800 that took place yesterday at the American Association for Cancer Research (“AACR”) Annual Meeting 2023 in Orlando, FL (to view the poster, titled Inhibition of HSF1 Demonstrates Therapeutic Efficacy in Preclinical PDX Models of Human Cholangiocarcinoma, click here).

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “Cancer of the bile duct, or cholangiocarcinoma (“CCA”), is a serious unmet medical need for which new treatment options are greatly needed. With approximately 10,000 new cases per year in the United States, the clinical management of CCA is complex, with only about 30% of patients eligible for surgical resection and the rest with unresectable disease, which carries a dismal prognosis with a median survival of less than 1 year. Unfortunately, approximately 60% of the patients that do undergo surgical resection experience disease recurrence and face similar outcomes.” Mr. Bentsur concluded, “We are excited about the data generated as we continue to evaluate clinical development opportunities for NXP800.”

Dr. Rory L. Smoot, MD, Mayo Clinic, who led the research, added: “We are encouraged by the robust preclinical activity demonstrated by NXP8000 in these CCA PDX models, which we believe serve as good indicators for potential clinical benefit. CCA is a very difficult to treat disease with poor outcomes and today’s results provide promise for patients in the future.”

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is a clinical-stage, oral small molecule under development for the treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma and additional solid tumor types. The FDA granted Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma. NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor with an Investigational New Drug (“IND”) application pending.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Nuvectis Pharma, Inc.’s current expectations, estimates, and projections about future events and trends that we believe may affect our business, financial condition, results of operations, prospects, business strategy, and financial needs. The outcome of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict and include statements regarding the preclinical data generated to date for NXP800, including the preclinical data in cholangiocarcinoma, and for NXP900, the Phase 1a data generated and the Phase 1b clinical expectations for NXP800, including the safety, tolerability and other observations from the NXP800 Phase 1a study and timing, and safety, tolerability and efficacy data from the NXP800 Phase 1b study, including statements regarding NXP800’s potential ability to become a therapeutic option for the treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma, ARID1a-mutated or wildtype cholangiocarcinoma, and potentially other cancer indications, and timing for the IND acceptance and commencement of the Phase 1 program for NXP900. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are subject to market and other conditions and described more fully in the section titled “Risk Factors” in our 2022 Form 10-K filed with the Securities and Exchange Commission (“SEC”). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contact

Ron Bentsur
Chairman, Chief Executive Officer and President
Tel: 201-614-3151
[email protected] 

Media Relations Contact

Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
[email protected] 

PHILADELPHIA, April 18, 2023 (GLOBE NEWSWIRE) — Harsco Corporation (NYSE: HSC), a global, market leading provider of environmental solutions for industrial and specialty waste streams, today announced that Company management will be participating in the following upcoming investor conferences:

• Oppenheimer’s 18
  
  ^th
  
  Annual Industrial Growth Conference (Virtual)
  Monday, May 8, 2023
• Gabelli 9
  
  ^th
  
  Annual Waste & Recycling Symposium (New York)
  Thursday, May 11, 2023

• KeyBanc Industrials & Basic Materials Conference (Boston)
  Thursday, June 1, 2023

• Stifel Cross Sector Insight Conference (Boston)
  Wednesday, June 7, 2023

About Harsco Corporation

Harsco Corporation is a global, market leader providing environmental solutions for industrial and specialty waste streams, and innovative technologies for the rail industry. Based at Two Logan Square, PA, the 13,000-employee company operates in more than 30 countries. Harsco’s common stock is a component of the S&P SmallCap 600 Index and the Russell 2000 Index. Additional information can be found at www.harsco.com.

Investor Contact  David Martin 1 267 946 1407 [email protected]

Media Contact Jay Cooney 1 267 857 8017 [email protected]